ArticleJournal of diabetes and metabolic disorders2026
GLP-1 receptor agonists in kidney transplant recipients with type 2 diabetes mellitus: a systematic review and meta-analysis on mortality and major adverse kidney events.
Article in Journal of diabetes and metabolic disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of GLP-1 receptor agonist therapy in the management of steroid-induced diabetes: a narrative review.Frontiers in clinical diabetes and healthcare · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used in patients with type 2 diabetes mellitus and chronic kidney disease. However, their safety and efficacy in kidney transplant recipients remain uncertain. This study aims to evaluate the impact of GLP-1 RAs on all-cause mortality, major adverse cardiovascular events (MACE), and major adverse kidney events (MAKE) in adult kidney transplant recipients. Methods: We conducted a systematic review and meta-analysis of retrospective cohort studies reporting outcomes in adult kidney transplant recipients treated with GLP-1 RAs. A comprehensive search of PubMed, Embase and Cochrane Library was performed up to July 2025. Studies were included if they reported on at least one of the following outcomes: all-cause mortality, MACE, or MAKE. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Results: A total of four retrospective cohort studies involving 27,153 were included. A total of 5,479 (20.2%) patients received GLP-1 RAs. The median follow-up period across studies ranged from 1.38 to 3.1 years. GLP-1 RAs treatment was associated with a significant reduction in all-cause mortality, with an aHR of 0.52 (95% CI: 0.32-0.85, I² = 86%; Conclusions: In kidney transplant recipients with type 2 DM, GLP-1 RAs appear to be associated with reduced risks of all-cause mortality and MAKEs. However, given the high heterogeneity across studies and the influence of a single large cohort, these findings should be interpreted with caution and considered exploratory. Prospective studies are needed to confirm the long-term safety and efficacy of GLP-1 RAs in this population. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01801-7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.